GlassScriptPhysician profile
Timothy J Lilly
NPI 1649258765
$3,677.76
in general payments reported to CMS, 2019-2025
31 companies · $942 in 2025
The $942 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $977 · 2020: $136 · 2021: $40.22 · 2022: $171 · 2023: $394 · 2024: $1,018 · 2025: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,353.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $478.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $466.42 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $417.18 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $352.09 | 2019-2025 | |
| Amgen INC. | $303.53 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.72 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $157.89 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Astrazeneca Pharmaceuticals LP | $147.22 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Exact Sciences Corporation | $114.05 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $108.78 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $91.74 | 2019-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.84 | 2019-2023 | Xifaxan, Trulance |
| Abbvie INC. | $79.30 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $62.97 | 2019-2025 | Eliquis, Camzyos |
| Dexcom, INC. | $60.47 | 2024-2025 | Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $50.86 | 2023 | Tymlos |
| Heartflow, INC. | $45.63 | 2024 | |
| Allergan, INC. | $44.16 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $43.79 | 2019-2025 | |
| Amarin Pharma, INC. | $41.41 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $34.15 | 2025 | Rexulti |
| Abbott Laboratories | $29.92 | 2021-2023 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $25.28 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $22.94 | 2025 | Unithroid |
| Lundbeck LLC | $21.71 | 2025 | Rexulti |
| Boston Scientific Corporation | $20.07 | 2025 | Watchman |
| Inspire Medical Systems, INC. | $18.32 | 2024 | Inspire |
| Grifols USA, LLC | $17.67 | 2025 | Prolastin-C Liquid |
| Esperion Therapeutics, INC. | $16.35 | 2025 | Nexletol |
| Pulmonx Corporation | $15.45 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Kowa Pharmaceuticals America, INC. | $12.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Lilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.